{{Rsnum
|rsid=6944165
|Gene=FLJ43663
|Chromosome=7
|position=131059593
|Orientation=plus
|GMAF=0.2989
|Gene_s=LRRC20
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 2.7 | 35.4 | 61.9
| HCB | 21.2 | 44.5 | 34.3
| JPT | 18.6 | 39.8 | 41.6
| YRI | 12.3 | 37.7 | 50.0
| ASW | 12.3 | 38.6 | 49.1
| CHB | 21.2 | 44.5 | 34.3
| CHD | 21.1 | 46.8 | 32.1
| GIH | 6.9 | 30.7 | 62.4
| LWK | 12.7 | 45.5 | 41.8
| MEX | 3.4 | 25.9 | 70.7
| MKK | 9.1 | 35.1 | 55.8
| TSI | 5.9 | 39.2 | 54.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6944165
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00009. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109385
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6944165
|overall_frequency_n=33
|overall_frequency_d=128
|overall_frequency=0.257812
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=25
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | Affy GenomeWide 6}}